News & Events
-
October 28, 2020
C-Path and EATRIS To Collaborate on RDCA-DAP
C-Path has signed a Memorandum of Understanding with EATRIS, the European infrastructure for translational medicine, to accelerate drug development for rare diseases by increasing the efficiency of translation of potential therapeutics through preclinical and clinical development …
-
September 21, 2020
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA)
C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA) Drug Development Tool Research Grant in support of the qualification of the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA) as a self-reported measure of symptom severity in individuals diagnosed with major depressive disorder (MDD). C-Path’s PRO...... -
September 3, 2020
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the PROMIS® Short Form v2.1—Physical Function-Multiple Sclerosis 15a (PROMIS PFMS—15a)
C-Path’s Patient-Reported Outcome (PRO) Consortium announced today it has been awarded a U.S. Food and Drug Administration (FDA) Drug Development Tool Research Grant in support of the qualification of the PROMIS® Short Form v2.1—Physical Function-Multiple Sclerosis 15a (PROMIS PFMS—15a) as a self-reported measure of physical function in individuals diagnosed with all forms of multiple...... -
August 25, 2020
Biomarkers of Crohn’s Disease to Support the Development of New Therapeutic Interventions
C-Path’s Crohn’s Disease Biomarkers Pre-Consortium funded by The Helmsley Charitable Trust is proud to announce its first publication in the journal Inflammatory Bowel Diseases titled, “Biomarkers of Crohn’s Disease to Support the Development of New Therapeutic Interventions.” The result of collaboration among experts in Crohn’s disease, including academia, health care institutes, foundations, public advocacy groups, industry and regulatory bodies, this work has identified biomarkers that can be used as drug development tools to advance clinical trials in IBD and potentially improve patient care.
-
August 21, 2020
C-Path’s PKDOC and The PKD Foundation Set to Collaborate Once Again
Polycystic Kidney Disease (PKD) is an inherited disorder in which clusters of cysts develop in the kidneys. There are more than 200,000 US cases diagnosed each year and many people with this condition have kidney failure by age 60. To meet the challenge in discovering treatments for PKD, C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) is excited to announce a collaboration with The PKD Foundation, who’s mission is to fund research, advocate for patients and build a community for all impacted by PKD. The agreement renews the significant collaboration between C-Path and The PKD Foundation to facilitate existing and new mutually agreed upon programs to accelerate the pace and reduce the cost of medical product development for the diagnosis and treatment of PKD. Learn more about PKDOC.